Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
accessible, affix, Agriculture, anemia, Annex, annum, antitumor, biomarker, Biophysical, border, Britain, Canada, cancelled, capillary, CE, chart, chemotherapy, closure, cohort, Colorado, combat, consecutive, constitutionality, Council, CRL, cut, drawn, drew, dual, Dustin, earthquake, England, equitable, estate, explicit, extrapolate, famine, fatigue, floating, flood, Florida, fluid, foster, fragment, GLP, gouging, Great, halt, Hampshire, harmonized, heard, HHS, HMR, immigration, immunodepleting, inevitable, inflation, instability, insurrection, invoking, Ireland, IVDD, IVDR, leadership, leak, lender, lessor, loan, manmade, MDR, meant, median, Mexico, Michael, military, mimic, mission, noncancelable, onsite, opposed, OS, Oxford, paint, pledge, PR, preexisting, premise, prerequisite, pressing, real, refinanced, registry, reinforce, repaid, repay, repayment, reply, resuming, riot, Russia, scan, Scotland, SD, sequencing, SI, Silicon, SIP, solve, sparing, St, SVB, tie, traceability, Ukraine, unencumbered, uniform, unpaid, unrest, Valley, Vermont, violence, Washington, wholesale, WSJ
Removed:
aberrant, absolute, accompanied, activator, addressable, anal, applicant, attributed, autoimmunity, begun, breast, cGMP, Conversely, deployment, diseased, displayed, dysregulated, elegant, encumbered, entail, Europe, exhausted, extracellular, growing, highlighted, imbalance, immunology, immunosuppressive, impede, implicated, inflammation, intracellular, investor, leasing, lesion, lessee, localization, maximal, microenvironment, modality, occurred, overactive, partner, pathogenic, payroll, peripheral, pertaining, phenotype, preferentially, prototypic, reaction, reactivate, reactive, recurrence, shorten, SubQ, suggest, susceptibility, systemically, tolerogenic, transplant, turnover, vulvar
Filing tables
Filing exhibits
CUE similar filings
Filing view
External links
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Nos. 333-229140 and 333-23957) on Form S-3 and Registration Statements (Nos. 333-224018, 333-230282 and 333-237140) on Form S-8 of Cue Biopharma, Inc. of our report dated March 16, 2022, relating to the consolidated financial statements of Cue Biopharma, Inc. and Subsidiary appearing in this Annual Report on Form 10-K of Cue Biopharma, Inc. for the year ended December 31, 2021.
/s/ RSM US LLP
Boston, Massachusetts
March 16, 2022